🔄 Standardization could reduce risks and streamline workflows, enhancing visibility and compliance in CGT.
🔍 TrakCel’s approach offers automated tracking and audit-ready reports, which will significantly benefit the industry and improve patient safety.
Introduction:
The article discusses the critical need for standardization in the supply chain management of cell and gene therapy (CGT) as the sector evolves from experimental to widespread therapeutic applications. Amid increasing complexity in the supply chain, the development of standardized solutions can enhance efficiency, reduce risks, and ensure compliance throughout the various stages of therapy administration.
- The CGT landscape has grown more complex with over 1,851 clinical trials in 2024, necessitating improved management protocols due to increased risk of dosing errors.
- A lack of standardization in software across personalized therapies creates confusion and risks among healthcare professionals.
- TrakCel’s OCELLOS is a software solution developed to address these challenges by enhancing workflow consistency and regulatory compliance through standardization of handling processes.
- OCELLOS enables essential tracking features such as chain-of-identity and chain-of-custody monitoring, audit readiness, and automation of supply chain activities.
- Collaborative forums by TrakCel aim to foster industry-wide best practices that promote standardization and ultimately improve patient safety and therapy delivery.
Conclusion:
The article emphasizes that while complete standardization in CGT supply chains may be unattainable, efforts towards greater consistency will streamline processes, mitigate risks, and enhance safety for patients. The introduction of OCELLOS exemplifies a proactive approach to managing the complexities of CGT, suggesting a promising direction for the industry amidst its ongoing evolution.
